Health Insurance Fund on differences in expensive medicines: Checks have been requested more than once

The National Health Insurance Fund (NHIF) has affirmed its consistent efforts to ensure fair drug pricing, stating that it has 'repeatedly requested checks on the pricing of medicines' from relevant institutions. This clarification comes in response to public revelations concerning substantial price disparities for expensive medications used to treat rare diseases, which are procured by hospitals and subsequently covered by the NHIF.

This issue highlights a critical concern within Bulgaria's healthcare system: the potential for inflated costs in the procurement of life-saving, yet costly, pharmaceuticals. The NHIF's stance suggests a proactive, albeit perhaps not always effective, approach to monitoring and controlling expenditure on these vital treatments. The fund's emphasis on its repeated requests for investigations indicates a desire to address the discrepancies and ensure that public funds are used judiciously.

From a Bulgarian perspective, as reported by Dnevnik, the focus is on accountability and transparency in the healthcare sector. The NHIF's position underscores the importance of rigorous oversight, especially when dealing with medications for rare conditions where patient access is paramount and costs are inherently high. The fund's call for checks implies a need for greater scrutiny of hospital procurement practices and pharmaceutical pricing strategies to prevent any undue financial burden on the state and, ultimately, on taxpayers.